Form 4: NextCure Director John G. Houston Acquires Stock Options

Director John G. Houston acquired 18,700 stock options in NextCure, Inc. on June 20, 2024.

Summary

• On June 20, 2024, John G. Houston, a director of NextCure, Inc., acquired 18,700 stock options.
• The exercise price of these options is $1.5.
• The options vest fully on the earlier of June 20, 2025, and the date of the 2025 Annual Meeting of Stockholders.
• The options expire on June 19, 2034.
• Following the transaction, Houston directly owns 18,700 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction filing, indicating a director's acquisition of stock options, which can be seen as a positive but doesn't provide strong positive or negative signals.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting and expiration dates of the options.

Industry Context

This transaction is a routine disclosure related to executive compensation and insider trading regulations. It reflects standard practices for incentivizing company leadership.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued employment and market value.

Stakeholder Impact

• The acquisition of stock options by a director could potentially increase shareholder confidence.

Key Dates